Stage II Lung Squamous Cell Carcinoma Complicated by Immunotherapy-Induced Cutaneous Lupus

Patient Info: Anonymized, male, 60s | Stage II

Imaging showed a treatment response. After radical radiotherapy, camrelizumab was discontinued because of immune-mediated subacute cutaneous lupus, and the lung cancer was placed under active monitoring.

PubMed CentralRead more →

HER2-Positive Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative, PR-negative, HER2-positive

Under surveillance with no evidence of breast-cancer recurrence for 2 years.

PubMed CentralRead more →

Bilateral inflammatory breast cancer treated with pembrolizumab and surgery

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Bilateral breast cancers had different biology: right side ER/PR-positive and HER2 FISH-negative; left side triple-negative/HER2 1+.

As of March 2025, she had no recurrence 6 months after bilateral mastectomy, bilateral axillary lymph node dissection, thoracoabdominal flap closure, and planned postmastectomy radiation for Stage IIIC bilateral inflammatory breast cancer.

PubMed CentralRead more →

Stage III Colorectal Cancer: Chloe's Survivor Story

Patient Info: Chloe, Female, Under 40 | Stage III

Biomarkers: Rare genetic disorder/gene reported; exact gene not stated

Chloe was diagnosed with Stage III colon cancer in February 2024 after emergency surgery. After surgery, stoma creation, and 3 months of chemotherapy, she was told she was in remission in June 2024 and remained on surveillance.

The Patient StoryRead more →

Stage 3 squamous cell lung cancer: complete remission on tislelizumab monotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Squamous lung cancer markers: P40 positive, TTF-1/Napsin A negative, Ki-67 75%. PD-1/PD-L1 testing was not done.

As of April 2024, enhanced CT, tumor-marker decline, and clinical assessment supported complete remission by iRECIST after chemoimmunotherapy and tislelizumab monotherapy.

PubMed CentralRead more →

Stage II Colorectal Cancer: Kristin's Survivor Story

Patient Info: Kristin, Female | Stage II

Kristin had Stage II colon cancer treated with emergency surgery and 4 months of chemotherapy. Her February 2022 scan confirmed no evidence of disease, and as of March 2025 she had recently celebrated 3 years cancer-free.

The Patient StoryRead more →

Mark: Stage III Colorectal Cancer

Patient Info: Mark, Male, Under 40 | Stage III

Biomarkers: Lynch syndrome negative

As of March 2025, Mark was sharing his story after surgery and intensive chemotherapy for Stage IIIB colon cancer and had been declared to have no evidence of disease in 2021.

The Patient StoryRead more →

Stage III Colorectal Cancer: Heather's Survivor Story

Patient Info: Heather Russell, Female, Under 40 | Stage III

In her fifth year of remission at the time of the 2025 story after treatment for Stage III rectal cancer; she had returned to family and working life, with some lasting treatment effects.

Cleveland ClinicRead more →

Stage III Colorectal Cancer: Courtney's Survivor Story

Patient Info: Courtney Vigars, Female, Under 40 | Stage III

In her fifth year of remission at the time of the 2025 story after transanal surgery, radiation, and chemotherapy for Stage III rectal cancer; she had returned to an active working life.

Cleveland ClinicRead more →

Stage III Colorectal Cancer: Mark's Survivor Story

Patient Info: Mark, Male, Under 40 | Stage III

Biomarkers: Tumor genetic testing negative; Lynch syndrome not detected

Mark had Stage III right-sided colon cancer treated with surgery and chemotherapy. He has been considered no evidence of disease since finishing chemotherapy in spring 2021 and had passed the 4-year post-surgery milestone as of March 2025.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Bill's Patient Story

Patient Info: Bill, Male, 40s | Stage IV

Metastatic Site: Liver | Lungs | Brain

As of March 2025, Bill was living with incurable Stage IV colon cancer after liver, lung, and brain involvement, with ongoing chemotherapy and lifelong maintenance treatment.

The Patient StoryRead more →

Metastatic lung adenocarcinoma: complete remission on nivolumab complicated by immune-mediated diabetes

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung tumor: EGFR wild type, ALK rearrangement not detected. Immune-mediated diabetes: islet/GAD antibodies negative and C-peptide undetectable.

Metastatic Site: brain (cerebellum and occipital lobe); liver

As of March 2025, serial CT and MRI scans through October 2023 showed no evidence of oncologic disease after nivolumab, while immune-mediated diabetes was controlled with basal-bolus insulin.

PubMed CentralRead more →

Stage IV ROS1 Lung Adenocarcinoma: Luna's Patient Story

Patient Info: Luna, Female, 50s | Stage IV

Biomarkers: ROS1 rearrangement; EGFR negative; ALK negative

Metastatic Site: liver; bones

Luna had Stage IV ROS1-positive lung adenocarcinoma with liver and bone metastases. After progression on initial chemotherapy, crizotinib led to tumor shrinkage and controlled her cancer for almost 12 years as of March 2025.

The Patient StoryRead more →

Stage IV HER2-Positive Breast Cancer: Stephani's Survivor Story

Patient Info: Stephani St. Cyr, Female | Stage IV

Biomarkers: HER2-targeted treatments reported; no inherited cancer gene mutation found.

Metastatic Site: Bone; liver; brain

As of March 2025, Stephani had Stage IV metastatic breast cancer involving bone, liver, and brain, had no evidence of disease since July 2021, and continued HER2-targeted/systemic therapy.

Stage IV KRAS Colorectal Cancer: Bill's Patient Story

Patient Info: Bill, Male, 40s | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: liver; lung; brain

Bill has Stage IV KRAS G12A-mutated colon cancer with liver, lung, and brain metastases. After multiple surgeries, ablation, Gamma Knife, and repeated chemotherapy, tumors shrank and he moved to lifelong maintenance chemotherapy every 2 weeks as of March 2025.

The Patient StoryRead more →

Stage IV HER2-Positive Breast Cancer: Anne's Patient Story

Patient Info: Anne Keane, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: bones, liver

Anne had an extraordinary response to first-line treatment for metastatic HER2-positive breast cancer and remained on the same HER2-targeted therapy for 6 years.

Dana-FarberRead more →

Stage IV KRAS Lung Cancer: Rosemary's Patient Story

Patient Info: Rosemary Conway, female, 60s | Stage IV

Biomarkers: KRAS mutation

After 14 months on daraxonracib in a clinical trial, Rosemary’s Stage IV lung cancer had stopped growing and she had returned to walking and lifting weights.

Dana-FarberRead more →

Synchronous breast and right colon cancers: response to carboplatin-paclitaxel and surgery

Patient Info: Anonymized, Female, 70+

Biomarkers: Breast cancer was ER/PR positive, HER2 negative

As of March 2025, 9-month follow-up showed no local recurrence or distant metastasis after multimodal treatment, while she continued anastrozole.

PubMed CentralRead more →

Shannin: Stage IV Colorectal Cancer

Patient Info: Shannin, Female, Under 40 | Stage IV

Biomarkers: Tumor-marker testing used to select immunotherapy

Metastatic Site: Liver

As of March 2025, Shannin was living with Stage IV colon cancer with cancer remaining in the liver while receiving chemotherapy and tumor-marker-matched immunotherapy.

The Patient StoryRead more →

Extended-stage small cell lung cancer with breast metastasis: complete response after pembrolizumab

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TMB-high, microsatellite stable; TP53/PTEN mutations, and SOX2/PIK3CA/FGF12 amplifications.

Metastatic Site: breast

As of March 2025, she had maintained complete response for more than 18 months on pembrolizumab monotherapy after prior cisplatin/irinotecan response.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Shannin's Patient Story

Patient Info: Shannin, Female, Under 40 | Stage IV

Biomarkers: Genetic testing negative; tumor-marker match for immunotherapy reported, exact marker not stated

Metastatic Site: liver; ovaries; peritoneum

Shannin has palliative Stage IV metastatic colorectal cancer with liver, ovarian, and peritoneal involvement. As of March 2025, she was continuing chemotherapy plus immunotherapy, had responded enough to keep treatment going, but still needed liver-directed options and did not qualify for a Canadian liver-pump trial.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Tamara's Patient Story

Patient Info: Tamara, Female, 50s | Stage IV

Biomarkers: FAP / APC mutation; reported de novo APC mutation

Metastatic Site: liver; lungs; retroperitoneal area reported initially

Tamara has Stage IV FAP/APC-associated colon cancer with liver and lung metastases. After chemotherapy plus immunotherapy, her numbers dropped sharply, lung disease cleared, and liver disease shrank but remained active; as of March 2025, she was continuing maintenance treatment.

The Patient StoryRead more →

Edie: Stage III Colorectal Cancer

Patient Info: Edie, Female, 50s | Stage III

As of March 2025, Edie had recovered after chemotherapy, radiation, lower anterior resection, temporary ileostomy, and reversal; lymph nodes were negative, margins were clean, and follow-up scans and colonoscopies had remained clear.

The Patient StoryRead more →

Tamara: Stage IV Colorectal Cancer

Patient Info: Tamara, Female, 50s | Stage IV

Biomarkers: APC mutation; familial adenomatous polyposis

Metastatic Site: Liver | Lungs

As of March 2025, Tamara was living with Stage IV FAP-associated colon cancer involving the liver and lungs after completing 12 cycles of chemotherapy and immunotherapy.

The Patient StoryRead more →